Affected by the mutant strains such as Omicron, the global epidemic has occurred repeatedly. Covid-19 virus detection enterprises have returned to the spotlight again and are not popular in the secondary market. Driven by strong market demand, a new round of production expansion is already on the way.
On January 12, an Xu Biology (688075) announced that it planned to use the over raised fund of 508 million yuan to invest in the R & D and production project of in vitro diagnostic reagents and diagnostic instruments, so as to meet the rapidly growing demand for real-time detection reagents and instruments in the world.
In the covid-19 detection reagent sector, an Xu biology has harvested four trading limits in five days since January 6, and its share price has doubled. A few days ago, the company released a performance forecast. It is estimated that the net profit in 2021 will be 658 million yuan – 790 million yuan, with a year-on-year increase of 1.41% – 21.69%.
5 billion yuan to expand production
The announcement shows that the total investment of the project invested and constructed by Anxi biology is expected to be 508 million yuan, all from over raised funds, and the construction cycle is about 2 years.
In fact, the above-mentioned project is a new round of capacity expansion of the company in the technology of the initial raised investment project. On November 18, 2021, an Xu biology first entered the scientific innovation board and successfully raised 1.2 billion yuan, including a net amount of 1.056 billion yuan and an over raised fund of 597 million yuan. According to the plan, the raised funds are intended to be used for projects such as the annual output of 300 million class II and III medical devices, in vitro diagnostic reagents, instruments and supporting products (hereinafter referred to as the “annual output of 300 million in vitro diagnostic reagents and supporting projects”), the intelligent technical transformation of the production of in vitro diagnostic reagents and POCT instruments, and the upgrading and construction of technology R & D center, At present, an annual output of 300 million in vitro diagnostic reagents and supporting projects have been basically completed and put into normal operation.
An Xu biology said that the global demand for real-time detection reagents and detection instruments has increased greatly, especially in the foreign market. After the completion of the project, the production scale will be further expanded and the automation level of the production line will be improved. At present, the company’s overseas sales account for more than 90% all year round. According to the latest news, An Xu biological New Coronavirus antigen nasal examination reagent (self testing) has obtained EU CE certification, and can be sold in the EU market.
The production expansion project will be implemented by Zhejiang Xumin Biotechnology Co., Ltd., a wholly-owned subsidiary, with a total construction area of about 85000 m2. It will be equipped with production plants, staff dormitories, basements and other buildings. It is expected to add 949 sets of equipment and 9 sets of software. In addition to covid-19 virus detection, Asahi bio’s real-time detection reagent can also be used in drug detection, infectious disease detection, chronic disease detection, pregnancy detection, tumor detection, myocardial detection, biochemical detection, allergen detection and other fields.
detection reagent is again popular
The repeated global epidemic, superimposed on the impact of the recent Omicron mutant strain, and the high demand for detection reagents, ignited the market again. In recent days, the detection reagent sector has risen sharply, and individual stocks such as Anxi biology, Hangzhou Alltest Biotech Co.Ltd(688606) , Beijing Hotgen Biotech Co.Ltd(688068) , Zhejiang Orient Gene Biotech Co.Ltd(688298) have increased by more than 50%.
At the production level, the reporter of securities times · e company actually explored a number of testing reagent production enterprises and witnessed the hot scene of factory full production and surge in recruitment; On the news side, the major reagent manufacturers continue to receive the news of international certification, making the international market more imaginative.
In December 2021, An Xu’s bio New Coronavirus antigen nasal examination reagent (self testing) obtained the CE certification of EU and could be sold in the EU market. In September 1st, Hangzhou Biotest Biotech Co.Ltd(688767) New Coronavirus antigen self testing reagent product was obtained from the European Union CE certification. In October 15th, its COVID-19 virus antigen self testing reagent product was not certified by Australia TGA. Beijing Hotgen Biotech Co.Ltd(688068) covid-19 virus antigen detection kit was earlier certified by the German Federal Institute of drugs and medical devices (bfarm) for free detection at home, and successively obtained the self-test registration / filing of EU CE, UK MHRA, France ansm and other economies in the second half of 2021; The antigen self-test kits of Andon Health Co.Ltd(002432) , Zhejiang Orient Gene Biotech Co.Ltd(688298) and Aikang biology have been approved by FDA. However, many companies have made it clear that the product certification fee is not exclusive to the company and still faces the risk of fierce market competition in the international market.
It is worth mentioning that due to different technical routes and market-oriented, the performance of major testing reagent companies varies. Beijing Hotgen Biotech Co.Ltd(688068) due to the sharp rise in the performance of centralized release of overseas orders, it is expected that the net profit in 2021 will reach 2 billion yuan – 2.35 billion yuan, with a year-on-year increase of 16.8-20 times; An Xu biology shows a steady growth trend. It is estimated that the net profit in 2021 will be 658 million yuan – 790 million yuan, with a year-on-year increase of 1.41% – 21.69%; Zhejiang Orient Gene Biotech Co.Ltd(688298) the net profit in the first three quarters was 3.9 billion yuan, a year-on-year increase of nearly 5 times; Hangzhou Biotest Biotech Co.Ltd(688767) in the first three quarters, the net profit was 720 million yuan, a year-on-year increase of 101.88%.
